2026 Q1 -tulosraportti
Vain PDF
75 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sitten · MuokattuAn announcement has been issued today, regarding legislation that was just adopted in July. Source from Bundesrat, In the top sections it states that it is not entirely clarified with regard to the people who are undergoing treatment with flower medicine. A little further down you can read that the pharmacies have already anticipated the law change and have sent out letters about the upcoming law change. That is naturally why yesterday we could ascertain that several pharmacies have received Weeco Astrum 10/10 in stock. see under the heading : Current information from health practice https://bdcan.de/cannabisblueten-gkv/- ·1 päivä sittenI have inserted this article, because here it states, in black and white, that those persons who today receive flower medicine, can get a prescription immediately, for cannabis oils. They are not included in the 6-month quarantine. That is also why we can already see that doctors have started to prescribe cannabis oils. There are only 5 months until the subsidy for flower medicine stops. Therefore, I expect that the cannabis shops that only have flowers in their assortment will start to get oils. If you don't want to spend time reading the entire article, you can just read what Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA) has said about the above. Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA), wrote on LinkedIn: "Many patients who currently receive prescription cannabis medicine do not fall under these approved indications." https://cannabishealthnews.co.uk/2026/07/14/germany-bans-medical-cannabis-flower-from-reimbursement-and-mandates-six-month-trial-for-extracts/I repeat again, again and gladly do it again. The people who have been in a treatment course with Cannabis flowers are beyond the 6 months because they HAVE been in a treatment course with cannabis flowers. The people who have received a prescription for cannabis flowers, but who are not documented as ill, they lose the subsidy and must pay themselves. The people who will be affected, i.e., that they have to wait 6 months before they can get a prescription for ex. Weeco Astrum 10/10, are those who are just entering the treatment system now. Everyone else who has been in treatment systems has completed the 6-month quarantine. The above is the direct reason why we can state today that several pharmacies have received Weeco Astrum 10/10 in stock. As well as we will also see online stores that currently only have flower medicine in their assortment also getting oils and extracts. Either you can scroll down and read what I have written about spin and that it's not about people losing their subsidy. It's only about many people losing a lot of money because flower medicine loses the subsidy, or you can start digging yourself into what is actually happening in Germany.
- ·1 päivä sittenStock status Can One Stop has gone from 3 to 5 pharmacies that have Weeco Astrum 10/10 permanently in stock. They still send to the remaining pharmacies, 519 pharmacies, with which they have a collaboration. Green Medical has gone from 3 to 5 pharmacies. Green Medical sends to these 5 pharmacies and to private addresses. Weed.de has gone from 3 to 7 pharmacies Weed.de also sends to private addresses. Canngo has gone from 4 to 6 pharmacies Canngo also sends the oil to private addresses. Flowzz has gone from 3 to 5 pharmacies. Flowzz also sends the oil to private addresses. It seems that Weeco Pharma's campaign for Weeco Astrum 10/10 is working. As well as that doctors also, gradually, have started to find alternatives to flower medicine.
- ·16.7.I have come across this study that Weed.de has conducted and which was published yesterday. As you can see, the people who receive a prescription for Weeco Astrum10-10 (the others too) have gone through a long treatment process, several years in fact, before they receive a prescription for Weeco Astrum10-10, which is in line with the arguments I have put forward previously, that the new legislative proposal has NO impact whatsoever on Stenocare's earnings in Germany. When it says that people lose their prescription, it is only flowers and vaporizers that lose their subsidy. It is Weed.de that is responsible for the study and they lose a lot of money because the subsidy is removed from flowers and vaporizers, but as I said, Stenocare only earns money from oil in Germany, and therefore everything continues as usual for Stenocare. https://cannabib.de/schlagzeilen/cannabis-auf-kassenrezept-2026-gkv-reform/Now I have found where it is stated in writing that growth in Germany will be long-term, which has been reinforced by the webcasts where it is announced that they expect earnings of 11-13 million in total, in 2026, and that it is Denmark that will drive the earnings. Regarding Germany, it must take its course. The following was written when Stenocare announced the collaboration with Weeco Pharma. Together, the collaboration forms a strong platform for long-term growth in the German market for medical cannabis Even though Stenocare has not provided guidance, they have stated that they expect earnings in 2026, and have downplayed the earnings in Germany, saying it is between 11-13 million kroner. But if they see that it will be more than 13 million for 2026, then they must tell the shareholders via a press release, regardless of what they have called their announcement. Stenocare must NOT withhold such information until the financial report is published, because the share price is based on the information that TS and PJ have stated to the market. They have very clearly downplayed the earnings in Germany, and we can very clearly see that there have been a lot of sales in Germany. We can see that there have been good earnings in Germany, because Weeco Astrum 10-10 is not an order item, but a stock item. The oil only becomes a stock item when there is a certain flow in the inventory, and we have seen that 3 pharmacies have been sold out in May, 8 times within 14 days, plus the oil was back in stock within 24 hours, this can only happen because Weeco Pharma has control over their infrastructure. (I know that there are some rules about silence before financial reports are published, but this silence must be broken if the financial report is to be adjusted upwards) https://www.inderes.dk/releases/stenocare-stenocare-kicks-off-strategic-partnership-with-weeco-to-launch-new-astrum-oil-product-in-germany
- ·14.7. · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.
We probably won't agree, and that's fine. I just still think you're dismissing a potential risk a bit too quickly. I still believe that if the law ends up being implemented in the draft that has been presented, then I do not see it as an advantage – neither for new patients nor for the possibility of continued growth in Germany. Let's see what happens over the summer. I certainly hope the law is not passed in its current form, as I believe it will be a clear deterioration for the patients.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
75 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sitten · MuokattuAn announcement has been issued today, regarding legislation that was just adopted in July. Source from Bundesrat, In the top sections it states that it is not entirely clarified with regard to the people who are undergoing treatment with flower medicine. A little further down you can read that the pharmacies have already anticipated the law change and have sent out letters about the upcoming law change. That is naturally why yesterday we could ascertain that several pharmacies have received Weeco Astrum 10/10 in stock. see under the heading : Current information from health practice https://bdcan.de/cannabisblueten-gkv/
- ·1 päivä sittenI have inserted this article, because here it states, in black and white, that those persons who today receive flower medicine, can get a prescription immediately, for cannabis oils. They are not included in the 6-month quarantine. That is also why we can already see that doctors have started to prescribe cannabis oils. There are only 5 months until the subsidy for flower medicine stops. Therefore, I expect that the cannabis shops that only have flowers in their assortment will start to get oils. If you don't want to spend time reading the entire article, you can just read what Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA) has said about the above. Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA), wrote on LinkedIn: "Many patients who currently receive prescription cannabis medicine do not fall under these approved indications." https://cannabishealthnews.co.uk/2026/07/14/germany-bans-medical-cannabis-flower-from-reimbursement-and-mandates-six-month-trial-for-extracts/I repeat again, again and gladly do it again. The people who have been in a treatment course with Cannabis flowers are beyond the 6 months because they HAVE been in a treatment course with cannabis flowers. The people who have received a prescription for cannabis flowers, but who are not documented as ill, they lose the subsidy and must pay themselves. The people who will be affected, i.e., that they have to wait 6 months before they can get a prescription for ex. Weeco Astrum 10/10, are those who are just entering the treatment system now. Everyone else who has been in treatment systems has completed the 6-month quarantine. The above is the direct reason why we can state today that several pharmacies have received Weeco Astrum 10/10 in stock. As well as we will also see online stores that currently only have flower medicine in their assortment also getting oils and extracts. Either you can scroll down and read what I have written about spin and that it's not about people losing their subsidy. It's only about many people losing a lot of money because flower medicine loses the subsidy, or you can start digging yourself into what is actually happening in Germany.
- ·1 päivä sittenStock status Can One Stop has gone from 3 to 5 pharmacies that have Weeco Astrum 10/10 permanently in stock. They still send to the remaining pharmacies, 519 pharmacies, with which they have a collaboration. Green Medical has gone from 3 to 5 pharmacies. Green Medical sends to these 5 pharmacies and to private addresses. Weed.de has gone from 3 to 7 pharmacies Weed.de also sends to private addresses. Canngo has gone from 4 to 6 pharmacies Canngo also sends the oil to private addresses. Flowzz has gone from 3 to 5 pharmacies. Flowzz also sends the oil to private addresses. It seems that Weeco Pharma's campaign for Weeco Astrum 10/10 is working. As well as that doctors also, gradually, have started to find alternatives to flower medicine.
- ·16.7.I have come across this study that Weed.de has conducted and which was published yesterday. As you can see, the people who receive a prescription for Weeco Astrum10-10 (the others too) have gone through a long treatment process, several years in fact, before they receive a prescription for Weeco Astrum10-10, which is in line with the arguments I have put forward previously, that the new legislative proposal has NO impact whatsoever on Stenocare's earnings in Germany. When it says that people lose their prescription, it is only flowers and vaporizers that lose their subsidy. It is Weed.de that is responsible for the study and they lose a lot of money because the subsidy is removed from flowers and vaporizers, but as I said, Stenocare only earns money from oil in Germany, and therefore everything continues as usual for Stenocare. https://cannabib.de/schlagzeilen/cannabis-auf-kassenrezept-2026-gkv-reform/Now I have found where it is stated in writing that growth in Germany will be long-term, which has been reinforced by the webcasts where it is announced that they expect earnings of 11-13 million in total, in 2026, and that it is Denmark that will drive the earnings. Regarding Germany, it must take its course. The following was written when Stenocare announced the collaboration with Weeco Pharma. Together, the collaboration forms a strong platform for long-term growth in the German market for medical cannabis Even though Stenocare has not provided guidance, they have stated that they expect earnings in 2026, and have downplayed the earnings in Germany, saying it is between 11-13 million kroner. But if they see that it will be more than 13 million for 2026, then they must tell the shareholders via a press release, regardless of what they have called their announcement. Stenocare must NOT withhold such information until the financial report is published, because the share price is based on the information that TS and PJ have stated to the market. They have very clearly downplayed the earnings in Germany, and we can very clearly see that there have been a lot of sales in Germany. We can see that there have been good earnings in Germany, because Weeco Astrum 10-10 is not an order item, but a stock item. The oil only becomes a stock item when there is a certain flow in the inventory, and we have seen that 3 pharmacies have been sold out in May, 8 times within 14 days, plus the oil was back in stock within 24 hours, this can only happen because Weeco Pharma has control over their infrastructure. (I know that there are some rules about silence before financial reports are published, but this silence must be broken if the financial report is to be adjusted upwards) https://www.inderes.dk/releases/stenocare-stenocare-kicks-off-strategic-partnership-with-weeco-to-launch-new-astrum-oil-product-in-germany
- ·14.7. · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.We probably won't agree, and that's fine. I just still think you're dismissing a potential risk a bit too quickly. I still believe that if the law ends up being implemented in the draft that has been presented, then I do not see it as an advantage – neither for new patients nor for the possibility of continued growth in Germany. Let's see what happens over the summer. I certainly hope the law is not passed in its current form, as I believe it will be a clear deterioration for the patients.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
75 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sitten · MuokattuAn announcement has been issued today, regarding legislation that was just adopted in July. Source from Bundesrat, In the top sections it states that it is not entirely clarified with regard to the people who are undergoing treatment with flower medicine. A little further down you can read that the pharmacies have already anticipated the law change and have sent out letters about the upcoming law change. That is naturally why yesterday we could ascertain that several pharmacies have received Weeco Astrum 10/10 in stock. see under the heading : Current information from health practice https://bdcan.de/cannabisblueten-gkv/
- ·1 päivä sittenI have inserted this article, because here it states, in black and white, that those persons who today receive flower medicine, can get a prescription immediately, for cannabis oils. They are not included in the 6-month quarantine. That is also why we can already see that doctors have started to prescribe cannabis oils. There are only 5 months until the subsidy for flower medicine stops. Therefore, I expect that the cannabis shops that only have flowers in their assortment will start to get oils. If you don't want to spend time reading the entire article, you can just read what Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA) has said about the above. Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA), wrote on LinkedIn: "Many patients who currently receive prescription cannabis medicine do not fall under these approved indications." https://cannabishealthnews.co.uk/2026/07/14/germany-bans-medical-cannabis-flower-from-reimbursement-and-mandates-six-month-trial-for-extracts/I repeat again, again and gladly do it again. The people who have been in a treatment course with Cannabis flowers are beyond the 6 months because they HAVE been in a treatment course with cannabis flowers. The people who have received a prescription for cannabis flowers, but who are not documented as ill, they lose the subsidy and must pay themselves. The people who will be affected, i.e., that they have to wait 6 months before they can get a prescription for ex. Weeco Astrum 10/10, are those who are just entering the treatment system now. Everyone else who has been in treatment systems has completed the 6-month quarantine. The above is the direct reason why we can state today that several pharmacies have received Weeco Astrum 10/10 in stock. As well as we will also see online stores that currently only have flower medicine in their assortment also getting oils and extracts. Either you can scroll down and read what I have written about spin and that it's not about people losing their subsidy. It's only about many people losing a lot of money because flower medicine loses the subsidy, or you can start digging yourself into what is actually happening in Germany.
- ·1 päivä sittenStock status Can One Stop has gone from 3 to 5 pharmacies that have Weeco Astrum 10/10 permanently in stock. They still send to the remaining pharmacies, 519 pharmacies, with which they have a collaboration. Green Medical has gone from 3 to 5 pharmacies. Green Medical sends to these 5 pharmacies and to private addresses. Weed.de has gone from 3 to 7 pharmacies Weed.de also sends to private addresses. Canngo has gone from 4 to 6 pharmacies Canngo also sends the oil to private addresses. Flowzz has gone from 3 to 5 pharmacies. Flowzz also sends the oil to private addresses. It seems that Weeco Pharma's campaign for Weeco Astrum 10/10 is working. As well as that doctors also, gradually, have started to find alternatives to flower medicine.
- ·16.7.I have come across this study that Weed.de has conducted and which was published yesterday. As you can see, the people who receive a prescription for Weeco Astrum10-10 (the others too) have gone through a long treatment process, several years in fact, before they receive a prescription for Weeco Astrum10-10, which is in line with the arguments I have put forward previously, that the new legislative proposal has NO impact whatsoever on Stenocare's earnings in Germany. When it says that people lose their prescription, it is only flowers and vaporizers that lose their subsidy. It is Weed.de that is responsible for the study and they lose a lot of money because the subsidy is removed from flowers and vaporizers, but as I said, Stenocare only earns money from oil in Germany, and therefore everything continues as usual for Stenocare. https://cannabib.de/schlagzeilen/cannabis-auf-kassenrezept-2026-gkv-reform/Now I have found where it is stated in writing that growth in Germany will be long-term, which has been reinforced by the webcasts where it is announced that they expect earnings of 11-13 million in total, in 2026, and that it is Denmark that will drive the earnings. Regarding Germany, it must take its course. The following was written when Stenocare announced the collaboration with Weeco Pharma. Together, the collaboration forms a strong platform for long-term growth in the German market for medical cannabis Even though Stenocare has not provided guidance, they have stated that they expect earnings in 2026, and have downplayed the earnings in Germany, saying it is between 11-13 million kroner. But if they see that it will be more than 13 million for 2026, then they must tell the shareholders via a press release, regardless of what they have called their announcement. Stenocare must NOT withhold such information until the financial report is published, because the share price is based on the information that TS and PJ have stated to the market. They have very clearly downplayed the earnings in Germany, and we can very clearly see that there have been a lot of sales in Germany. We can see that there have been good earnings in Germany, because Weeco Astrum 10-10 is not an order item, but a stock item. The oil only becomes a stock item when there is a certain flow in the inventory, and we have seen that 3 pharmacies have been sold out in May, 8 times within 14 days, plus the oil was back in stock within 24 hours, this can only happen because Weeco Pharma has control over their infrastructure. (I know that there are some rules about silence before financial reports are published, but this silence must be broken if the financial report is to be adjusted upwards) https://www.inderes.dk/releases/stenocare-stenocare-kicks-off-strategic-partnership-with-weeco-to-launch-new-astrum-oil-product-in-germany
- ·14.7. · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.We probably won't agree, and that's fine. I just still think you're dismissing a potential risk a bit too quickly. I still believe that if the law ends up being implemented in the draft that has been presented, then I do not see it as an advantage – neither for new patients nor for the possibility of continued growth in Germany. Let's see what happens over the summer. I certainly hope the law is not passed in its current form, as I believe it will be a clear deterioration for the patients.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt